- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Dokta Yu Baofa da wata tawaga daga Amurka sun buga wata kasida a cikin Mujallar Nazarin Gastroenterology Research and Practice.
2025-02-11
Likita Yu Baofa da tawagar Amurka sun buga labarin tare da buga labarin kimantawa da yawa na autoantibodies zuwa ƙari hade antigens a matsayin yiwuwar gano cutar kansar pancreatic a cikin Journal of Gastroenterology Research and Practice.
Manufar wannan binciken shine don kimanta mahimmancin asibiti na autoantibodies akan GNA11, MSLN, GNAS, CEBPA, MDM2, p16, Sui1, Calnuc, PTEN a cikin ciwon daji na pancreatic (PC). Jimlar samfurori na 33 daga marasa lafiya na PC da samfurori na 45 daga abubuwan sarrafawa na yau da kullum (NC) an haɗa su, kuma an gano nau'in autoantibodies guda 9 ta amfani da enzyme-linked immunosorbent assay (ELISA). Yi la'akari ta amfani da sigogi da yawa a cikin daidaikun mutane ko a hade. Ban da anti GNAS da anti calNUC, matakan duk sauran autoantibodies sun fi girma fiye da waɗanda ke cikin ƙungiyar kulawa ta al'ada. Idan aka kwatanta da ƙungiyar kulawa ta al'ada (4.9%), mitoci na autoantibodies huɗu, MSLN, p16, PTEN, da Sui1, sun ƙaru sosai, a 75.8%, 66.7%, 30.3%, da 27.3%, bi da bi. Ƙarfin waɗannan autoantibodies don rarrabe yanki a ƙarƙashin ROC curve (AUC) ya fito daga 0.666 zuwa 0.884, tare da anti-p16 (AUC na 0.884) da kuma MSLN (AUC na 0.857) yana nuna aikin bincike mafi ƙarfi. Haɗin anti-MSLN da anti-p16 na iya inganta ji na ganewar asali.
Bugu da ƙari, duka MSLN da Sui1 autoantibodies sun ragu a cikin marasa lafiya na PC bayan chemotherapy. Guda huɗu na autoantibodies akan MSLN, p16, Sui1 da PTEN sun nuna yuwuwar alamun gano cutar kansar pancreatic, wanda anti MSLN da anti p16 sune mafi kyau. Haɗuwa da waɗannan autoantibodies guda biyu yana nuna mafi girman tattalin arziki da yuwuwar aiki. Mahimmancin raguwar ƙwayoyin rigakafi na autoantibodies akan MSLN da Sui1 a cikin marasa lafiya na PC bayan chemotherapy yana buƙatar ƙarin bincike.
Binciken da ke da alaƙa da ƙwayoyin cuta na ƙwayoyin cuta yana ba da mahimman bayanai don gwajin farko, ganewar asali, da kuma kula da ciwace-ciwace. Masanin ilimin kimiyya Yu Baofa ya yi amfani da kwayoyin cutar kansa a cikin jiyya fiye da shekaru 20 da suka wuce.
